Please login to the form below

Not currently logged in
Email:
Password:

Viela Bio

This page shows the latest Viela Bio news and features for those working in and with pharma, biotech and healthcare.

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition

Viela's portfolio of assets includes FDA-approved NMOSD therapy Uplizna. Horizon Therapeutics has entered into a definitive agreement to acquire Viela Bio for $3bn, in an effort to strengthen its ... Viela Bio spun out of AstraZeneca’s Medimmune

Latest news

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....